Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.

Abstract

Asthma is a complex airways disease with a wide spectrum which ranges from eosinophilic (Th2 driven) to mixed granulocytic (Th2/Th17 driven) phenotypes. Mixed granulocytic asthma is a cause of concern as corticosteroids often fail to control this phenotype. Different kinases such as Brutons's tyrosine kinase (BTK) and IL-2 inducible T cell kinase (ITK) play a pivotal role in shaping allergic airway inflammation. Ibrutinib is primarily a BTK inhibitor, however it is reported to be an ITK inhibitor as well. In this study, we sought to determine the effect of Ibrutinib on Th1, Th17 and Th2 immune responses in a cockroach allergen extract (CE)-induced mixed granulocytic (eosinophilic and neutrophilic) mouse model in preventative mode. Ibrutinib attenuated neutrophilic inflammation at a much lower doses (25-75 μg/mouse) in CE-induced mixed granulocytic asthma whereas Th2/Th17 immune responses remained unaffected at these doses. However, at a much higher dose, i.e. 250 μg/mouse, Ibrutinib remarkably suppressed both Th17/Th2 and lymphocytic/neutrophilic/eosinophilic airway inflammation. At molecular level, Ibrutinib suppressed phosphorylation of BTK in neutrophils at lower doses and ITK in CD4 + T cells at higher doses in CE-treated mice. Further, effects of Ibrutinib were compared with dexamethasone on CE-induced mixed granulocytic asthma in therapeutic mode. Ibrutinib was able to control granulocytic inflammation along with Th2/Th17 immune response in therapeutic mode whereas dexamethasone limited only Th2/eosinophilic inflammation. Thus, Ibrutinib has the potential to suppress both Th17/Th2 and neutrophilic/eosinophilic inflammation during mixed granulocytic asthma and therefore may be pursued as alternative therapeutic option in difficult-to-treat asthma which is resistant to corticosteroids.

• Authors: Ahmed Nadeem, Sheikh F Ahmad, Naif O Al-Harbi, Khalid E Ibrahim, Nahid Siddiqui, Mohammed M Al-Harbi, Sabry M Attia, Saleh A Bakheet
• Journal: Pharmacological research (Pharmacol Res) Vol. 148 Pg. 104441 (10 2019) ISSN: 1096-1186 [Electronic] Netherlands
• PMID: 31505252 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2019 Elsevier Ltd. All rights reserved.

Chemical References

• Allergens
• Anti-Asthmatic Agents
• Cytokines
• Interleukin-2
• Plant Extracts
• Protein-Tyrosine Kinases
• Agammaglobulinaemia Tyrosine Kinase
• Btk protein, mouse
• emt protein-tyrosine kinase

Topics

• Agammaglobulinaemia Tyrosine Kinase (antagonists & inhibitors, immunology)
• Allergens (immunology)
• Animals
• Anti-Asthmatic Agents (pharmacology)
• Asthma (chemically induced, drug therapy, immunology, metabolism)
• Cockroaches (immunology)
• Cytokines (immunology, metabolism)
• Disease Models, Animal
• Granulocytes (immunology, metabolism)
• Inflammation (drug therapy, immunology, metabolism)
• Interleukin-2 (antagonists & inhibitors, immunology)
• Male
• Mice
• Mice, Inbred BALB C
• Neutrophils (drug effects, immunology, metabolism)
• Plant Extracts (immunology)
• Protein-Tyrosine Kinases (immunology, metabolism)
• Th17 Cells (drug effects, immunology, metabolism)
• Th2 Cells (drug effects, immunology, metabolism)